Interleukin-2 receptor subunit alpha


  • Accession: P01589
  • Swissprot: IL2RA_HUMAN
  • Organism: Homo sapiens
  • Gene: IL2RA
  • Target class: Membrane receptor

Drug Relations:

a recombinant human IL-2, marketed for the treatment of metastatic renal cell carcinoma; BAY 50-4798 is a variant Bioactivity details MOA
Basiliximab functions as an IL-2 receptor antagonist by binding with high affinity to the alpha chain of the high affinity IL-2 receptor complex and inhibiting IL-2 binding. Basiliximab is specifically targeted against IL-2Ralpha, which is selectively expressed on the surface of activated T-lymphocytes. This specific high affinity binding of basiliximab to IL-2Ralpha competitively inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection. Bioactivity details MOA
An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS. Bioactivity details MOA
denileukin diftitox
more potent, truncated form of DAB(486)-IL-2; inhibit HIV-1 RNA production in infected cells Bioactivity details MOA